Clinical trial
Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence With Treatment in Overactive Bladder (OAB) Patients Prescribed Betmiga® - A Multicenter Non-interventional Post Authorisation Study (PAS)
NCT02320773 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence With Treatment in Overactive Bladder (OAB) Patients Prescribed Betmiga® - A Multicenter Non-interventional Post Authorisation Study (PAS)
- Lead sponsor
- Astellas Pharma Europe Ltd.
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 25, 2014
- Completion date
- July 27, 2016
- Enrollment
- 863 (actual)
- Sites
- 60
Conditions
As the registry lists them; a condition with its own page is linked.
overactive bladder, urgency incontinence, urinary bladder diseases, urinary bladder overactive, urologic diseases